|
18 Nov 2019 |
The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
|
|
16 Nov 2019 |
Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program
|
|
16 Nov 2019 |
Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma
|
|
16 Nov 2019 |
Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program
|
|
13 Nov 2019 |
Kiadis Pharma changes strategy to focus solely on development of Natural Killer (NK) Cell therapeutics and terminates development of ATIR101
|
|
12 Nov 2019 |
Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting
|
|
12 Nov 2019 |
Solid Biosciences Provides SGT-001 Program Update
|
|
12 Nov 2019 |
Biomica Reports Positive Preliminary Results in Animal Studies in Its Immuno-oncology Program
|
|
12 Nov 2019 |
BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis
|
|
11 Nov 2019 |
Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World’s First Stem Cell Therapy Trial using HepaStem™ in Acute-on-Chronic Liver Failure
|
|
10 Nov 2019 |
Autolus Therapeutics Presents Preclinical Data on AUT06NG at the SITC Annual Meeting
|
|
10 Nov 2019 |
Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
|
|
08 Nov 2019 |
Torque Presents New Preclinical Data for Three Deep-Primed Cellular Immunotherapy Programs, Including Newly Unveiled Deep TLR, at SITC 2019 Meeting
|
|
08 Nov 2019 |
Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019
|
|
08 Nov 2019 |
Talaris Therapeutics Presents Data Supporting Potential of FCR001 to Prevent Recurrence of Kidney-Related Autoimmune Disease in Kidney Transplant Recipients
|
|
08 Nov 2019 |
NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019
|
|
07 Nov 2019 |
Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer
|
|
07 Nov 2019 |
Early Results from First-In-U.S. Trial of CRISPR-Edited Immune Cells for Cancer Patients Suggest Safety of Approach
|
|
06 Nov 2019 |
4D pharma plc: Preliminary Safety and Clinical Observations From Its Phase I/II Study of MRx0518 in Combination With KEYTRUDA
|
|
06 Nov 2019 |
Cartesian Initiates CAR-T Clinical Trial in Myasthenia Gravis
|
|
06 Nov 2019 |
Dystrogen Therapeutics Announces That Treatment With Dystrophin Expressing Chimeric (DEC) Cells Improves Cardiac Function in Preclinical Duchenne's Study
|
|
06 Nov 2019 |
Checkmate Pharmaceuticals Presents Positive Clinical Data with CMP-001 at The 34th Annual Meeting of The Society for Immunotherapy of Cancer (SITC)
|
|
06 Nov 2019 |
AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Program and Reports Compelling Preclinical Data Supporting the Potential of its Dual-Vector Technology
|
|
06 Nov 2019 |
Evelo Biosciences Reports Further Positive EDP1815 Interim Clinical Data in Patients with Psoriasis at High Dose in Phase 1b Trial
|
|
06 Nov 2019 |
Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
